lung cancer
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
April 5, 2024Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically …
Merck completes acquisition of Harpoon Therapeutics for $650m
March 12, 2024Business Services Harpoon Therapeutics, Merck, Oncology, lung cancer
Merck, known as MSD outside of the US and Canada, has announced that it has completed the acquisition of Harpoon …
AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment
February 19, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Tagrisso for the treatment of adult patients …
Vergent Bioscience shares phase 2 data for VGT-309
January 29, 2024Research and Development Oncology, VGT-309, Vergent Bioscience, lung cancer
Vergent Bioscience has announced new data from a phase 2 trial of VGT-309, the company’s investigational tumour-targeted fluorescent imaging agent. …
FDA approves BMS’s Augtyro for lung cancer treatment
November 16, 2023Medical Communications FDA, Oncology, bristol myers squibb, lung cancer
Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) for the treatment …
Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment
September 1, 2023Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer
Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …
AstraZeneca’s lung cancer drug gains EU approval
May 28, 2021Medical Communications AstraZeneca, EU, lung cancer, oncology
AstraZeneca’s Tagrisso (osimertinib) has been approved in the EU for the adjuvant treatment of adult patients with early-stage (IB, II …
Novartis’ canakinumab fails to improve lung cancer survival in Phase III study
March 9, 2021Manufacturing and Production Cancer, Novartis, lung cancer
Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …
Opdivo scores NICE recommendation in two non-small cell lung cancer indications
September 17, 2020Sales and Marketing NICE, lung cancer, opdivo
NICE has announced its recommendation of Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for the treatment of two non-small cell …
Genetech scores sixth FDA approval in lung cancer with Gavreto
September 7, 2020Sales and Marketing Cancer, FDA, Genentech, lung cancer
Genentech’s once-daily oral therapy Gavreto (pralsetinib) has secured FDA backing in the treatment of metastatic rearranged during transfection (RET) fusion-positive …
FDA approval for Jazz and PharmaMar’s Zepzelca in metastatic small cell lung cancer
June 17, 2020Manufacturing and Production, Research and Development, Sales and Marketing Cancer, FDA, PharmaMar, Zepzelca, jazz pharma, lung cancer
The FDA has awarded approval to Jazz Pharma and PharmaMar for Zepzelca (lurbinectedin) as a treatment for metastatic small cell …
NICE greenlights Roche’s Rozlytrek for ROS1+ advanced non-small cell lung cancer
June 15, 2020Sales and Marketing NICE, Roche, Rozlytrek, UK, lung cancer
Roche’s Rozlytrek (entrectinib) has secured recommendation for NHS use in England and Wales after NICE backed the drug in final …
NICE reverses previous stance to recommend Roche’s Tecentriq in extensive-stage small-cell lung cancer
May 27, 2020Research and Development, Sales and Marketing NICE, Roche, lung cancer, tecentriq
NHS patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC) in England and Wales will soon have access to a new …
Phase 3 Libtayo monotherapy trial halted early due to strong benefit in advanced non-small cell lung cancer
April 29, 2020Research and Development Cancer, Libtayo, Regeneron, Sanofi, lung cancer
A Phase 3 study of Sanofi and Regeneron’s Libtayo (cemiplimab) as a monotherapy for advanced or metastatic non-small cell lung …
FDA immunotherapy first with the approval of AZ’s Imfinzi in first-line extensive-stage small cell lung cancer
March 30, 2020Sales and Marketing AstraZeneca, Cancer, FDA, Imfinzi, lung cancer, pharma
AstraZeneca has seized FDA approval for its immune checkpoint inhibitor Imfinzi (durvalumab) in the first-line treatment of extensive-stage small cell …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
